180160-93-4

Usage

Uses

As the specific applications of 6-Chloro-3H-spiro[isobenzofuran-1,4'-piperidine] are still under investigation, the following uses are potential areas of interest based on its current status as a compound with therapeutic potential:
Used in Pharmaceutical Research:
6-Chloro-3H-spiro[isobenzofuran-1,4'-piperidine] is used as a potential therapeutic agent for its unique spiro structure, which may offer novel avenues for the treatment of various medical conditions. Its synthesis and properties are being studied to understand its potential in drug development.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 6-Chloro-3H-spiro[isobenzofuran-1,4'-piperidine] is used for exploring its biological activity and evaluating its efficacy in treating specific diseases or conditions. 6-Chloro-3H-spiro[isobenzofuran-1,4'-piperidine]'s unique structure may provide insights into new drug design and therapeutic strategies.
Used in Organic Chemistry:
6-Chloro-3H-spiro[isobenzofuran-1,4'-piperidine] is utilized in organic chemistry for studying its synthesis methods and understanding the reactivity and properties of spiro amine derivatives. This knowledge can contribute to the advancement of organic synthesis techniques and the discovery of new chemical compounds.

Upstream product

• 936-08-3 2-bromo-4-chlorobenzoic acid 
• 3612-20-2 1-phenylmethyl-4-piperidone 
• 54595-72-1 1'-benzyl-6-chloro-spiro[isobenzofuran-1,4'-piperidin]-3-one 
• 644968-57-0 1'-benzyl-6-chloro-3H-spiro[2-benzofuran-1,4'-piperidine] 

Relevant academic research and scientific papers

INDOL-3-YL-CARBONYL-SPIRO-PIPERIDINE DERIVATIVES AS V1A RECEPTOR ANTAGONISTS

The invention relates to indol-3-yl-carbonyl-spiro-piperidine derivatives which act as V1a receptor antagonists and which are represented by Formula I: wherein the spiro-piperidine head group A and the residues R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions containing such compounds, methods for preparing the compounds and pharmaceutical compositions, and their use in the treatment of dysmenorrhea, hypertension, chronic heart failure, inappropriate secretion of vasopressin, liver cirrhosis, nephrotic syndrome, obsessive compulsive disorder, anxious and depressive disorders.

NOVEL TRICYCLIC SPIROPIPERIDINES OR SPIROPYRROLIDINES

The invention provides compounds of formula (I) wherein m, R1, n, R2, q, X, Y, Z, R3, R4, R5, R6, R7, R8, t and R9 are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

SPIROCYCLIC PIPERIDINES AS MCH1 ANTAGONISTS AND USES THEREOF

This invention is directed to compounds which are selective antagonists for melanin concentrating hormone-1 (MCH1) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention also provides a method of reducing the body mass of a subject which comprises administering to the subject an amount of a compound of the invention effective to reduce the body mass of the subject. This invention further provides a method of treating a subject suffering from depression and/or anxiety which comprises administering to the subject an amount of a compound of the invention effective to treat the subject=s depression and/or anxiety. This invention further provides a method of treating a subject suffering from a urinary disorder.